Asano S, Matsuda S, Hoshina S, Sakamoto S, Takeguchi N
Molecular Genetics Research Center, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.
J Biol Chem. 1999 Mar 12;274(11):6848-54. doi: 10.1074/jbc.274.11.6848.
2-Methyl-8-(phenylmethoxy)imidazo(1,2-a)pyridine-3acetonitrile+ ++ (SCH 28080) is a K+ site inhibitor specific for gastric H+,K+-ATPase and seems to be a counterpart of ouabain for Na+,K+-ATPase from the viewpoint of reaction pattern (i.e. reversible binding, K+ antagonism, and binding on the extracellular side). In this study, we constructed several chimeric molecules between H+,K+-ATPase and Na+,K+-ATPase alpha-subunits by using rabbit H+,K+-ATPase as a parental molecule. We found that the entire extracellular loop 1 segment between the first and second transmembrane segments (M1 and M2) and the luminal half of the M1 transmembrane segment of H+, K+-ATPase alpha-subunit were exchangeable with those of Na+, K+-ATPase, respectively, preserving H+,K+-ATPase activity, and that these segments are not essential for SCH 28080 binding. We found that several amino acid residues, including Glu-822, Thr-825, and Pro-829 in the M6 segment of H+,K+-ATPase alpha-subunit are involved in determining the affinity for this inhibitor. Furthermore, we found that a chimeric H+,K+-ATPase acquired ouabain sensitivity and maintained SCH 28080 sensitivity when the loop 1 segment and Cys-815 in the loop 3 segment of the H+,K+-ATPase alpha-subunit were simultaneously replaced by the corresponding segment and amino acid residue (Thr) of Na+,K+-ATPase, respectively, indicating that the binding sites of ouabain and SCH 28080 are separate. In this H+, K+-ATPase chimera, 12 amino acid residues in M1, M4, and loop 1-4 that have been suggested to be involved in ouabain binding of Na+, K+-ATPase alpha-subunit are present; however, the low ouabain sensitivity indicates the possibility that the sensitivity may be increased by additional amino acid substitutions, which shift the overall structural integrity of this chimeric H+,K+-ATPase toward that of Na+,K+-ATPase.
2-甲基-8-(苄氧基)咪唑并(1,2-a)吡啶-3-乙腈(SCH 28080)是一种对胃H⁺,K⁺-ATP酶具有特异性的钾离子位点抑制剂,从反应模式来看(即可逆结合、钾离子拮抗以及在细胞外侧结合),它似乎是哇巴因对钠离子,钾离子-ATP酶作用的对应物。在本研究中,我们以兔H⁺,K⁺-ATP酶为亲本分子,构建了H⁺,K⁺-ATP酶与钠离子,钾离子-ATP酶α亚基之间的几种嵌合分子。我们发现,H⁺,K⁺-ATP酶α亚基中第一和第二跨膜片段(M1和M2)之间的整个细胞外环1片段以及M1跨膜片段的腔内一半分别可与钠离子,钾离子-ATP酶的相应片段互换,同时保留H⁺,K⁺-ATP酶活性,并且这些片段对于SCH 28080的结合并非必需。我们发现,H⁺,K⁺-ATP酶α亚基M6片段中的几个氨基酸残基,包括Glu-822、Thr-825和Pro-829,参与决定对该抑制剂的亲和力。此外,我们发现,当H⁺,K⁺-ATP酶α亚基的环1片段和环3片段中的Cys-815分别同时被钠离子,钾离子-ATP酶的相应片段和氨基酸残基(Thr)取代时,嵌合的H⁺,K⁺-ATP酶获得了对哇巴因的敏感性并保持了对SCH 28080的敏感性,这表明哇巴因和SCH 28080的结合位点是分开的。在这种H⁺,K⁺-ATP酶嵌合体中,存在着已被认为参与钠离子,钾离子-ATP酶α亚基哇巴因结合的M1、M4以及环1-4中的12个氨基酸残基;然而,较低的哇巴因敏感性表明,通过额外的氨基酸取代可能会增加敏感性,这些取代会使这种嵌合H⁺,K⁺-ATP酶的整体结构完整性向钠离子,钾离子-ATP酶的方向转变。